First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.
Ravi VijRajneesh NathDaniel E H AfarMaría-Victoria MateosJesús G BerdejaMarc S RaabAndreas GuentherJoaquín Martínez-LópezAndrzej J JakubowiakXavier LeleuKatja WeiselShekman WongScott GulbransonJames P SheridanAnita ReddyBruno PaivaAnil SinghalJesús San F MiguelPhilippe MoreauPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These results demonstrate that ABBV-838 is safe and well-tolerated in patients with RRMM with a very limited efficacy.